David F. Wurtman

Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

ChinaBio LLC operates as an investment, consulting and media company which helps life science companies. It organizes life science investment and partnering conferences in China. The firm’s conferences comprise investor forums, partnering forums, executive workshops and SEED business plan competitions. It also offers consulting services, including China strategy development, market and competitive intelligence, technology survey and search, partnering arrangement, CRO and CMO selection, management, business strategy, funding strategy, assistance, collaboration agreements, in-licensing, out-licensing, the United States operations consulting services, investment analysis, due diligence and portfolio analysis. The company serves executives, entrepreneurs, investors, pharma and multinational companies. ChinaBio was founded in April 2007 by Greg B. Scott and James W. Larrick and is headquartered in Shanghai, China.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

EOS Biotechnology, Inc. develops therapeutic and diagnostic drugs. The company was founded by Herbert L. Heyneker, John Lowe, David H. Mack, David W. Martin, Richard Murray, and Stephen W. Weiss and is headquartered in Fermont, California.

Kineta, Inc. engages in the development of novel immuno-therapies. It develops a pipeline of therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA.

GlycoMira Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Salt Lake City, UT. The private company is dedicated to improving the standard of care and outcomes for patients with cancer and other inflammatory diseases. GlycoMira is developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. The company's lead drug candidate, GM-1111, has demonstrated potential to address unmet needs in solid tumor treatment and supportive care. The CEO of the company is William P. Tew.